Brief: Tela Bio Announces Publication Of 24-Month Bravo Study Results Demonstrating Benefits Of Ovitex® Reinforced Tissue Matrix In Hernia Repair
26/10/2022 12:08
Oct 26 (Reuters) - TELA Bio Inc TELA.O :
* TELA BIO ANNOUNCES PUBLICATION OF 24-MONTH BRAVO STUDY
RESULTS
DEMONSTRATING BENEFITS OF OVITEX® REINFORCED TISSUE MATRIX IN
HERNIA REPAIR
Source text for Eikon: ID:nGNX3gpb5T
Further company coverage: TELA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on TELA Bio
See all newsBrief: Tela Bio - Receives FDA 510(K) Clearance For Liora Monofilament Scaffold For Soft Tissue Reinforcement
Tela Bio Inc Reports Results For The Quarter Ended June 30: Earnings Summary
TELA Bio Q2 revenue falls on lower OviTex PRS volumes, withdraws outlook
Brief: TELA Bio Q2 Revenue USD 19.291 Million Vs. IBES Estimate USD 20 Million
Tela Bio Inc Expected To Post A Loss Of 18 Cents A Share: Earnings Preview